John F. Palma

2.1k total citations
54 papers, 1.5k citations indexed

About

John F. Palma is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John F. Palma has authored 54 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Cancer Research, 27 papers in Oncology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John F. Palma's work include Cancer Genomics and Diagnostics (39 papers), Lung Cancer Treatments and Mutations (24 papers) and Colorectal Cancer Treatments and Studies (16 papers). John F. Palma is often cited by papers focused on Cancer Genomics and Diagnostics (39 papers), Lung Cancer Treatments and Mutations (24 papers) and Colorectal Cancer Treatments and Studies (16 papers). John F. Palma collaborates with scholars based in United States, Germany and Switzerland. John F. Palma's co-authors include Gang Liu, Jennifer Beane, Frank Schembri, Vishal Shah, Avrum Spira, Jerome S. Brody, Xuemei Yang, Yuqiu Jiang, David B. Agus and Yixin Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

John F. Palma

47 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John F. Palma United States	18	634	602	588	456	141	54	1.5k
Marcella Baldewijns Belgium	20	389 0.6×	858 1.4×	622 1.1×	301 0.7×	72 0.5×	62	1.6k
Perry Maxwell United Kingdom	24	360 0.6×	530 0.9×	335 0.6×	676 1.5×	223 1.6×	63	1.6k
Min Huang United States	22	507 0.8×	598 1.0×	422 0.7×	735 1.6×	129 0.9×	94	1.8k
Arnaldo Arbini United States	25	396 0.6×	905 1.5×	248 0.4×	433 0.9×	159 1.1×	55	1.9k
Göran Elmberger Sweden	23	599 0.9×	571 0.9×	767 1.3×	914 2.0×	207 1.5×	51	2.0k
Joseph A. Pinto Peru	18	505 0.8×	622 1.0×	405 0.7×	703 1.5×	107 0.8×	90	1.6k
Elisabeth Dequeker Belgium	23	570 0.9×	458 0.8×	524 0.9×	388 0.9×	302 2.1×	76	1.7k
Xiaodong Teng China	24	260 0.4×	716 1.2×	482 0.8×	397 0.9×	142 1.0×	116	1.7k
Stuart C. Winter United Kingdom	19	704 1.1×	698 1.2×	260 0.4×	344 0.8×	61 0.4×	70	1.6k
Dolores Gallardo‐Rincón Mexico	18	219 0.3×	494 0.8×	275 0.5×	524 1.1×	96 0.7×	49	1.3k

Countries citing papers authored by John F. Palma

Since Specialization

Citations

This map shows the geographic impact of John F. Palma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Palma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Palma more than expected).

Fields of papers citing papers by John F. Palma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Palma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Palma. The network helps show where John F. Palma may publish in the future.

Co-authorship network of co-authors of John F. Palma

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Palma. A scholar is included among the top collaborators of John F. Palma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Palma. John F. Palma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ho, Hsiang‐Ling, Yuqiu Jiang, Chi‐Lu Chiang, et al.. (2022). Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. PLoS ONE. 17(4). e0267362–e0267362. 8 indexed citations

Patel, Rajesh, Hans-Peter Adams, Xueping Qu, et al.. (2022). Detection of minimal residual disease (MRD) in colorectal cancer (CRC) patients UICC stage II/III by ultra-deep sequencing of cfDNA from post-surgery plasma.. Journal of Clinical Oncology. 40(4_suppl). 26–26. 2 indexed citations

Zou, Wei, Stephanie J. Yaung, Marcus Ballinger, et al.. (2021). ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy. JCO Precision Oncology. 5(5). 827–838. 35 indexed citations

Feldkamp, Mirjam, et al.. (2021). Innovative Tumor Tissue Dissection Tool for Molecular Oncology Diagnostics. Journal of Molecular Diagnostics. 23(4). 399–406. 6 indexed citations

Max, Xiaoju, Johanna C. Bendell, Herbert I. Hurwitz, et al.. (2020). Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. 26(15). 4010–4017. 19 indexed citations

Ju, Christine, Bernd Hinzmann, Stephanie J. Yaung, et al.. (2020). 1356P Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumour DNA. Annals of Oncology. 31. S869–S869.

Jiang, John, Hans-Peter Adams, Mirjam Feldkamp, et al.. (2020). Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer. BMC Cancer. 20(1). 885–885. 11 indexed citations

Yaung, Stephanie J., Fergal Casey, Maureen Peterson, et al.. (2019). Evaluation of clonal hematopoiesis in late stage NSCLC using a next-generation sequencing panel targeting cancer genes.. Journal of Clinical Oncology. 37(15_suppl). 9050–9050. 1 indexed citations

Yaung, Stephanie J., Christine Ju, Liqiang Xi, et al.. (2019). P1.01-34 Early Assessment of Therapy Response in Non-Small Cell Lung Cancer (NSCLC) via Longitudinal ctDNA Analysis. Journal of Thoracic Oncology. 14(10). S369–S369. 1 indexed citations

10.

Gandara, David R., Wei Zou, Stephanie J. Yaung, et al.. (2019). An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK study. Annals of Oncology. 30. v642–v643.

11.

Jiang, John, Hans-Peter Adams, Lijing Yao, et al.. (2019). Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I–IV Non–Small Cell Lung Cancer. Journal of Molecular Diagnostics. 22(2). 228–235. 36 indexed citations

12.

Wu, Yi‐Long, Victor Lee, Chong Kin Liam, et al.. (2018). Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer. 126. 1–8. 35 indexed citations

13.

Yaung, Stephanie J., Lei Xi, Bernd Hinzmann, et al.. (2018). Ecological diversity indices as measurements of tumor heterogeneity correlates with clinical outcomes in late stage small cell lung cancer (SCLC). Annals of Oncology. 29. viii54–viii54. 1 indexed citations

14.

Yaung, Stephanie J., Alan Nicholas, Nicolas Sommer, et al.. (2018). Correlation of measurements of tumor heterogeneity based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) with clinical outcomes in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 36(15_suppl). 3545–3545. 1 indexed citations

15.

Keppens, Cleo, Partha Das, John F. Palma, et al.. (2016). Inter-Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma. Journal of Thoracic Oncology. 12(1). 1 indexed citations

16.

Fisher, Kevin E., C. M. S. Cohen, Momin T. Siddiqui, et al.. (2014). Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Human Pathology. 45(11). 2281–2293. 39 indexed citations

17.

Palma, John F., et al.. (2011). Mutational profiling of sporadic versus toxin-associated brain cancer formation: Initial findings using loss of heterozygosity profiling. International Journal of Hygiene and Environmental Health. 215(3). 427–433. 3 indexed citations

18.

Alexandrescu, Doru T, C. Lisa Kauffman, T. Jatkoe, et al.. (2010). Melanoma-Specific Marker Expression in Skin Biopsy Tissues as a Tool to Facilitate Melanoma Diagnosis. Journal of Investigative Dermatology. 130(7). 1887–1892. 9 indexed citations

19.

Jiang, Yuqiu, John F. Palma, David B. Agus, Yixin Wang, & Mitchell E. Gross. (2010). Detection of Androgen Receptor Mutations in Circulating Tumor Cells in Castration-Resistant Prostate Cancer. Clinical Chemistry. 56(9). 1492–1495. 105 indexed citations

20.

Zhou, Yunping, John F. Palma, Anthony Schweitzer, et al.. (2003). Overexpression of Repressive cAMP Response Element Modulators in High Glucose and Fatty Acid-treated Rat Islets. Journal of Biological Chemistry. 278(51). 51316–51323. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact